Study S001596

Effect of Tirzepatide on Alcohol Intake and Reward Processing in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06939088
Acronym: DUALPSYCHIATRY
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: RECRUITING
Enrollment: 108
Start: 2025-05-05
Primary completion: 2028-08-01
Lead sponsor: Anders Fink-Jensen, MD, DMSci
Conditions: Alcohol Use Disorder; Alcohol Abuse/Dependence; Alcohol Dependence; Alcoholism; Schizophrenia Disorders; Schizophrenia and Disorders With Psychotic Features; Schizophrenia and Schizophrenia Spectrum Psychosis; Schizophrenia
Interventions: DRUG:Tirzepatide; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: REGISTRY:U1111-1312-8134; REGISTRY:2024-518608-28-00

Registered primary outcomes

Change in heavy drinking days [From baseline to 16 weeks of treatment]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.